Quris-AI to Integrate Nortis’ Kidney-on-Chip Technology

Bio-artificial intelligence (AI) company Quris-AI announced an asset acquisition of Nortis (previously Numa Biosciences, Inc.) and plans to integrate Nortis’ Kidney-on-Chip technology with its Bio-AI Clinical Prediction Platform. The Kidney-on-Chip technology has been vetted by the National Center for Advancing Translational Sciences under the National Institutes of Health.

The Kidney-on-Chip models have established new standards for in-vitro drug testing and personalized medicine. They will be combined with Quris-AI’s advanced machine learning models and patented patient-on-chip system that can predict a human body’s reaction to drugs and reject potentially harmful drug candidates earlier in the development process.

Quris will also continue the exploratory technology collaborations Nortis has established with research institutes, pharmaceutical companies, and the US Food and Drug Administration to promote clinical research on kidney diseases. They aim to advance understanding and treatment of kidney diseases while supporting the broader Quris mission to improve drug safety prediction.